Dr Reddy's gets adverse ruling in U.S. over patent infringement case

"The court found that Dr Reddys proposed palonosetron hydrochloride 0.25 mg/5 ml infringes on certain claims of the U.S. patents.and that the asserted claims were not valid". The injection is used to help prevent nausea and vomiting due to chemotherapy. The court found that Dr. Reddy's Laboratories" proposed Palonosetron Hydrochloride 0.25 mg / 5 ml product infringes certain claims of United States patent numbers 7,94,7724; 8,729,094; and 9,066,980 and that the asserted claims of the "094 and "980 patents were not invalid". Helsinn Healthcare had then announced that as a result of the settlement, DRL will be permitted to market a generic version of Aloxi in the USA from September 30, 2018, or earlier "under certain circumstances".

Drug major Dr Reddy's Laboratories on Friday said there are no claims against the company for monetary damages after it received an unfavourable ruling in a United States court regarding a patent infringement case over anti-nausea injection Aloxi. However, Helsinn challenged the Indian company's NDA for palonosetron hydrochloride of strengths 0.25 milligram and 5 milliliters in a court.

A company spokesperson stated, "We are disappointed in the discussion and intend to pursue an appeal in due course".

Analysts were expecting the company to launch the new drug by the end of this fiscal year. The company's share price has touched 52-week low at Rs 2,803.5, a negative development for the USA market. Benchmark BSE Sensex was trading 37.63 points, or 0.13 per cent up at 28,193.19.



Other news